Selected article for: "approach safety efficacy and safety efficacy"

Author: Hotez, Peter J.; Corry, David B.; Bottazzi, Maria Elena
Title: COVID-19 vaccine design: the Janus face of immune enhancement
  • Cord-id: npzri0rh
  • Document date: 2020_4_28
  • ID: npzri0rh
    Snippet: Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy.
    Document: Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy.

    Search related documents:
    Co phrase search for related documents
    • acute sars cov respiratory syndrome coronavirus and ade induce: 1
    • acute sars cov respiratory syndrome coronavirus and ade promote: 1
    • acute sars cov respiratory syndrome coronavirus and ade result: 1
    • acute sars cov respiratory syndrome coronavirus and liver lung: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
    • acute sars cov respiratory syndrome coronavirus and lung eosinophil infiltration mononuclear cell: 1
    • ade antibody dependent enhancement and lung eosinophil infiltration mononuclear cell: 1